跳至主要内容
临床试验/EUCTR2006-003651-20-BE
EUCTR2006-003651-20-BE进行中(未招募)1 期

A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids. - Study of Zoster vaccine in subjects on chronic steroid maintenance

Merck Sharp & Dohme (Europe) Inc.0 个研究点目标入组 300 人开始时间: 2007年8月21日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Age=60 years.
  • 2.A history of varicella or long-term residence in a country with endemic VZV infection.
  • 3.Receiving chronic/maintenance systemic corticosteroid therapy at a daily dose equivalent of 5 to 20 mg of prednisone for at least 2 weeks immediately prior to enrolment.
  • 4.Expected to continue to receive a daily dose of 5 to 20 mg of prednisone or equivalent for the 6-week duration of the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1.Prior history of HZ
  • 2.Prior receipt of any varicella or zoster vaccine.
  • 3.Any use in the 8 weeks prior to vaccination or for 6 weeks postvaccination of concomitant immunosuppressive medications (e.g. corticosteroids >20 mg daily, chemotherapeutic agents, immunomodulating drugs, immunosuppressive treatments associated with solid organ or bone marrow transplantation.

研究者

相似试验